Finnadvance is a microtechnology and 3D biology solution company that develops microfluidic organ-on-chips for pharmaceutical drug research and development.
The microfluidic approach enables replicating precise biomechanical stimuli in vitro, with precise control of flow velocities and 3D ECM stiffness. With its microfluidic culture systems, the aim is to close the gap between in vitro studies and in vivo results. The devices are fully integrated microfluidics solutions compatible with microscope/imaging systems.
With founder and CEO Prateek Singh in the lead, the team includes highly experienced experts in the field of bioengineering, molecular and vascular biology as well as operational and commercial expertise. Finnadvance is based in Oulu, Finland, and joined NOME in 2021.